Detail akcie Xencor online

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Xencor Inc revenues increased 2% to $168.3M. Net loss increased from $55.2M to $126.1M. Revenues reflect Milestone segment increase from $5.5M to $88.5M, Research collaboration segment increase from $7M to $30.3M. Higher net loss reflects Research and Development - Balancing increase of 30% to $219.1M (expense), Stock-based Compensation in R&D increase of 9% to $34.5M (expense).